Cargando…

Pain management strategies for neuropathic pain in Fabry disease - a systematic review

BACKGROUND: Neuropathic pain is one of the key features of (classical) Fabry disease (FD). No randomized clinical trials comparing effectiveness of different pain management strategies have been performed. This review aims to give an overview of existing pain management strategies. METHODS: PubMed a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuller, Y., Linthorst, G. E., Hollak, C. E. M., Van Schaik, I. N., Biegstraaten, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766720/ https://www.ncbi.nlm.nih.gov/pubmed/26911544 http://dx.doi.org/10.1186/s12883-016-0549-8

Ejemplares similares

Erratum to: Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Poikilothermia in a 38-year-old Fabry patient
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Quality of life in patients with Fabry disease: a systematic review of the literature
por: Arends, Maarten, et al.
Publicado: (2015)

The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
por: Schuller, Y., et al.
Publicado: (2015)

Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
por: Arends, Maarten, et al.
Publicado: (2017)

Hearing loss in children with Fabry disease
por: Suntjens, E., et al.
Publicado: (2017)

Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain
por: Körver, Simon, et al.
Publicado: (2020)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Prevalence of symptoms in female Fabry disease patients: a case-control survey
por: Bouwman, Machtelt G., et al.
Publicado: (2012)

Relief of nocturnal neuropathic pain with the use of cannabis in a patient with Fabry disease
por: Bon, Martina, et al.
Publicado: (2023)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Management of neuropathic pain
por: Nishikawa, Noriko, et al.
Publicado: (2017)

Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases
por: Schuller, Y., et al.
Publicado: (2017)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

The Mini Mental State Examination does not accurately screen for objective cognitive impairment in Fabry Disease
por: Körver, Simon, et al.
Publicado: (2019)

Ion channels and pain in Fabry disease
por: Weissmann, Carina, et al.
Publicado: (2021)

Managing Neuropathic Pain in Dogs
por: Moore, Sarah A.
Publicado: (2016)

Alpha-Lipoic Acid as an Antioxidant Strategy for Managing Neuropathic Pain
por: Viana, Max Denisson Maurício, et al.
Publicado: (2022)

Toward Composite Pain Biomarkers of Neuropathic Pain—Focus on Peripheral Neuropathic Pain
por: Diaz, Monica M., et al.
Publicado: (2022)

Neuropathic pain: Mechanisms and therapeutic strategies
por: Petroianu, Georg A., et al.
Publicado: (2023)

Clinical practice guidelines for the management of neuropathic pain: a systematic review
por: Deng, Yunkun, et al.
Publicado: (2016)

Developments in the treatment of Fabry disease
por: van der Veen, Sanne J., et al.
Publicado: (2020)

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
por: Smid, Bouwien E, et al.
Publicado: (2011)

Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel
por: Burlina, Alessandro P, et al.
Publicado: (2011)

Utilization of PROMIS Neuropathic Pain Quality for Detection and Monitoring Neuropathic Pain in Heel Pain Patients
por: Joo, Peter Y., et al.
Publicado: (2023)

Cognitive functioning and depressive symptoms in Fabry disease: A follow‐up study
por: Körver, Simon, et al.
Publicado: (2020)

Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis
por: Di Stefano, Giulia, et al.
Publicado: (2021)

Review of duloxetine in the management of diabetic peripheral neuropathic pain
por: Smith, Timothy, et al.
Publicado: (2007)

Optogenetics: Emerging strategies for neuropathic pain treatment
por: Li, Siyu, et al.
Publicado: (2022)

Potential novel therapeutic strategies for neuropathic pain
por: Du, Zelu, et al.
Publicado: (2023)

Treatments of traumatic neuropathic pain: a systematic review
por: Yao, Chenglun, et al.
Publicado: (2017)

Advances in the interventional management of neuropathic pain
por: Varshney, Vishal, et al.
Publicado: (2021)

Update on Interventional Management of Neuropathic Pain: A Delphi Consensus of the Spanish Pain Society Neuropathic Pain Task Force
por: Serrano-Afonso, Ancor, et al.
Publicado: (2022)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Neuropathic pain
por: Khan, Junad
Publicado: (2016)

A Comprehensive Algorithm for Management of Neuropathic Pain
por: Bates, Daniel, et al.
Publicado: (2019)

Predictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry disease
por: Körver, Simon, et al.
Publicado: (2019)

Review of Mechanisms, Pharmacological Management, Psychosocial Implications, and Holistic Treatment of Pain in Fabry Disease
por: Rajan, Jonathan Niranjan, et al.
Publicado: (2021)

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
por: Vedder, Anouk C., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_8o1d4emhsb25t5ugv69391njds